Spectrum Pharmaceutecals Inc (SPPI)

[BarrellofHay]

Here are the enhertu results. Looks like the majority 86% were patients with her2-exon 20 mutations:

https://www.nejm.org/doi/full/10.1056/NEJMoa2112431

Spectrum seems to acknowledge the great results on page 16 and 17 of there fda report:

https://www.fda.gov/media/161677/download#page14

They seem to be arguing for approval for those who can’t take the adc and possibly as a third option. Not sure if the fda will buy this??? How many patients is that? They make no mention of her2-20g778 mutations from there last poster.